Furthermore, we demonstrated that SGLT2 inhibitor therapy for 24 weeks significantly decreased the ePV and eEV as assessed based on the body surface area of patients with T2DM and cardiovascular disease (CVD) [14] and in patients with T2DM and chronic HF [15]. This evidence concerns the gene SLC5A2 and cardiovascular disorder.